Old HIV drugs get a second look in Long-Term study

NCT ID NCT01125228

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This study compares three treatments for early HIV infection: zidovudine (AZT) alone, alpha-interferon alone, or both together. It aims to see which best lowers viral load, protects the immune system, and delays the first serious infection. About 180 adults with early HIV and healthy immune systems are taking part, with long-term follow-up to track outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

zidovudine (AZT) and alpha-interferon

What this could lead to

If successful, this could show which early HIV treatment better controls the virus and delays opportunistic infections.

What could go wrong

This is an older study from before modern HIV treatments (HAART), so results may not apply to current care. Side effects from both drugs can be significant.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States